selected scholarly activity
-
chapters
-
conferences
- EVALUATION OF VOLUMETRIC RESPONSE ASSESSMENT FROM STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR RENAL CELL CARCINOMA (RCC). Radiotherapy and Oncology. S67-S67. 2023
- FINAL RESULTS FROM A PROSPECTIVE RANDOMIZED PILOT TRIAL OF STEREOTACTIC BODY RADIATION THERAPY VERSUS RADIOFREQUENCY ABLATION FOR THE MANAGEMENT OF SMALL RENAL MASSES (RADSTER). Radiotherapy and Oncology. S52-S52. 2023
- FIVE-YEAR RENAL FUNCTION OUTCOMES AFTER SABR FOR PRIMARY RENAL CELL CARCINOMA: A REPORT FROM THE INTERNATIONAL RADIOSURGERY ONCOLOGY CONSORTIUM OF THE KIDNEY (IROCK). Radiotherapy and Oncology. S66-S67. 2023
- LONG-TERM TOXICITY IN PATIENTS RECEIVING RADIOTHERAPY FOR ULTRACENTRAL STAGE I NON-SMALL CELL LUNG CANCER - A SECONDARY ANALYSIS OF THE LUSTRE RANDOMIZED TRIAL. Radiotherapy and Oncology. S59-S59. 2023
- STEREOTACTIC RADIOTHERAPY FOR THE RE-TREATMENT OF PELVIC AND PARA-AORTIC DISEASE IN GYNECOLOGIC CANCERS. Radiotherapy and Oncology. S127-S128. 2023
- Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes. Clinical Oncology. 20-28. 2023
- Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics. 611-616. 2022
- 2022 American Society of Clinical Oncology (ASCO): Meeting highlights. Journal of the Canadian Urological Association. E499-504. 2022
- A PROSPECTIVE RANDOMIZED PARALLEL-CONTROLLED PILOT TRIAL OF STEREOTACTIC BODY RADIATION THERAPY VERSUS RADIOFREQUENCY ABLATION FOR THE MANAGEMENT OF SMALL RENAL MASSES - INITIAL RESULTS. Radiotherapy and Oncology. S17-S17. 2022
- International Consensus on Actions to Improve Lung Cancer Survival: Delphi Method in the International Cancer Benchmarking Partnership. Journal of Thoracic Oncology. S260-S261. 2022
- LONG-TERM OUTCOMES OF SABR TO PRIMARY RENAL CELL CARCINOMA: A MULTI- CENTRE ANALYSIS FROM THE INTERNATIONAL RADIOSURGERY ONCOLOGY CONSORTIUM FOR KIDNEY (IROCK). Radiotherapy and Oncology. S21-S22. 2022
- OUTCOMES OF RADIOTHERAPY ALONE FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) IN PATIENTS UNFIT FOR CHEMO-RADIOTHERAPY. Radiotherapy and Oncology. S39-S39. 2022
- RADIATION DOSE, TECHNIQUE, AND USE OF BRAIN RADIATION ON OVERALL SURVIVAL IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER. Radiotherapy and Oncology. S31-S31. 2022
- RADIOTHERAPY DOSE, FDG-PET UTILIZATION AND SURVIVAL OUTCOMES OF UNRESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC). ONTARIO POPULATION OUTCOMES OF CONTEMPORARY RADIOTHERAPY ALONE AND STANDARD OF CARE CHEMO-RADIOTHERAPY. Radiotherapy and Oncology. S59-S60. 2022
- STEREOTACTIC BODY RADIOTHERAPY FOR RENAL CELL CARCINOMA: ONCOLOGIC AND RENAL FUNCTION OUTCOMES. Radiotherapy and Oncology. S34-S34. 2022
- 196P An international consensus on actions to improve lung cancer survival: A clinical review by the international cancer benchmarking partnership (ICBP). Annals of Oncology. S119-S120. 2022
- A prospective randomized parallel-controlled pilot trial of stereotactic body radiation therapy versus radiofrequency ablation for the management of small renal masses.. Journal of Clinical Oncology. 363-363. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS398-TPS398. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2022
- Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology. 2022
- Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. European Urology. 693-700. 2021
- Cost-Effectiveness of SABR in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-COMET Trial. International Journal of Radiation Oncology Biology Physics. e344-e344. 2021
- Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease. International Journal of Radiation Oncology Biology Physics. e479-e479. 2021
- Real-World Outcomes of Chemoradiation and Consolidative Durvalumab in Unresectable Stage III Non-Small-Cell Lung Cancer — A Systematic Review. International Journal of Radiation Oncology Biology Physics. e438-e438. 2021
- The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario, Canada Between 2009-2017. International Journal of Radiation Oncology Biology Physics. e430-e430. 2021
- 52: Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease. Radiotherapy and Oncology. S25-S25. 2021
- COST-EFFECTIVENESS OF SABR IN OLIGOMETASTATIC CANCER: AN ECONOMIC ANALYSIS BASED ON LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL. Radiotherapy and Oncology. S13-S13. 2021
- REAL-WORLD OUTCOMES OF CHEMORADIATION AND CONSOLIDATIVE DURVALUMAB IN UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER - A SYSTEMATIC REVIEW. Radiotherapy and Oncology. S72-S72. 2021
- THE ROLE OF FDG-PET IN STAGING AND TREATMENT FOR STAGE III NSCLC IN ONTARIO BETWEEN 2009-2017. Radiotherapy and Oncology. S44-S44. 2021
- Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics. 1176-1184. 2021
- Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study. International Journal of Radiation Oncology Biology Physics. e115-e116. 2020
- Cardiac Toxicity in Central Non-Small Cell Lung Tumors treated with Stereotactic Body Radiation Therapy (SBRT) – Is there a “No-Flutter Zone”?. International Journal of Radiation Oncology Biology Physics. e138-e138. 2020
- Cost-Effectiveness of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) in the Treatment of Localized Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics. e393-e394. 2020
- Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). International Journal of Radiation Oncology Biology Physics. e887-e887. 2020
- Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464). International Journal of Radiation Oncology Biology Physics. S104-S104. 2020
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics. S88-S89. 2020
- Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics. 941-949. 2020
- A PHASE II MULTICENTRE TRIAL OF STEREOTACTIC RADIOTHERAPY FOR OLIGOPROGRESSION IN METASTATIC KIDNEY CANCER PATIENTS RECEIVING TYROSINE KINASE INHIBITOR THERAPY. Radiotherapy and Oncology. S7-S8. 2020
- A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL. Radiotherapy and Oncology. S87-S88. 2020
- CARDIAC MORBIDITY FOLLOWING RADICAL THORACIC CHEMORADIOTHERAPY FOR LOCALLY ADVANCED LUNG CANCER: A POPULATION-BASED COHORT STUDY. Radiotherapy and Oncology. S90-S90. 2020
- CARDIAC TOXICITY IN CENTRAL NON-SMALL CELL LUNG TUMOURS TREATED WITH STEREOTACTIC BODY RADATION THERAPY (SBRT) - IS THERE A "NO-FLUTTER ZONE"?. Radiotherapy and Oncology. S83-S83. 2020
- COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION (RFA) VERSUS STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN THE TREATMENT OF LOCALIZED RENAL CELL CARCINOMA. Radiotherapy and Oncology. S86-S86. 2020
- STEREOTACTIC ABLATIVE RADIOTHERAPY FOR THE COMPREHENSIVE TREATMENT OF OLIGOMETASTATIC CANCERS: LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL. Radiotherapy and Oncology. S7-S7. 2020
- SURGERY VERSUS SBRT FOR EARLY-STAGE NSCLC IN OCTOGENARIANS AND NONAGENARIANS: AN OVERALL SURVIVAL DIFFERENCE?. Radiotherapy and Oncology. S19-S19. 2020
- A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology. 2020
- A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. 985-992. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS761-TPS761. 2020
- A COMPARISON OF STEREOTACTIC BODY RADIOTHERAPY MODALITIES: VOLUMETRIC MODULATED ARC THERAPY VERSUS INTENSITY MODULATED RADIATION THERAPY IN TREATMENT OF KIDNEY CANCER. Radiotherapy and Oncology. S63-S63. 2019
- ENGAGING INTER-PROFESSIONAL COLLABORATION TO IMPROVE RESIDENT TREATMENT PLANNING KNOWLEDGE AND SKILLS. Radiotherapy and Oncology. S55-S55. 2019
- QUALITY OF LIFE OUTCOMES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) VERSUS STANDARD OF CARE PALLIATIVE TREATMENTS: A SECONDARY ANALYSIS OF THE SABR-COMET RANDOMIZED TRIAL. Radiotherapy and Oncology. S41-S41. 2019
- A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. E526-E527. 2019
- Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet. International Journal of Radiation Oncology Biology Physics. S100-S101. 2019
- Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics. S72-S73. 2019
- Stereotactic Body Radiotherapy for Large Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics. E257-E258. 2019
- Can the Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR) Predict Survival or Local Control in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC)? A Systematic Review. International Journal of Radiation Oncology Biology Physics. e706-e707. 2018
- Development of Best Practices of Peer Review in Lung Radiation Therapy. International Journal of Radiation Oncology Biology Physics. e461-e462. 2018
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects). International Journal of Radiation Oncology Biology Physics. S88-S89. 2018
- Identifying Potential Predictors of Late Renal Toxicity after Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics. e93-e93. 2018
- Lung SBRT Credentialing in the Canadian LUSTRE Randomized Trial. International Journal of Radiation Oncology Biology Physics. S235-S235. 2018
- Outcomes of Stereotactic Body Radiation Therapy for Abdominopelvic Oligometastases. International Journal of Radiation Oncology Biology Physics. e67-e68. 2018
- Patient-Reported Quality of Life Following Stereotactic Body Radiation Therapy for Primary Kidney Cancer: Results from a Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics. e93-e94. 2018
- Renal SABR in Patients with a Solitary Kidney: An Individual-Patient Pooled Analysis from the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics. S108-S109. 2018
- Systematic Review of the Incidence of Chest Wall Toxicity Following Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. e711-e711. 2018
- MS27.02 Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary?. Journal of Thoracic Oncology. S298-S299. 2018
- 127TiP Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574). Journal of Thoracic Oncology. S70-S71. 2018
- PO-0833: Dosimetric analysis of renal toxicity after stereotactic body radiotherapy for renal cell carcinoma. Radiotherapy and Oncology. S435-S435. 2018
- The International Radiosurgery Oncology Consortium for Kidney (IROCK) Multi-Centre Analysis of SABR for Primary RCC in Patients with or without Prior Nephrectomy. Asia-Pacific Journal of Clinical Oncology. 47-+. 2018
- A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics. S116-S116. 2017
- Identifying Barriers to Accrual in Radiation Oncology Randomized Trials: Insights From a Trial of Stereotactic Radiation for Oligometastatic Disease. International Journal of Radiation Oncology Biology Physics. E403-E403. 2017
- Individual Patient Data Meta-analysis of SBRT Kidney: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics. S153-S154. 2017
- Variability in lung SBRTcontours and doses at canadian institutions. Medical Physics. 4374-4374. 2017
- P1.07-050 Patterns of Relapse in Small Cell Lung Cancer (SCLC): A Retrospective Analysis of Outcomes from a Single Canadian Center. Journal of Thoracic Oncology. S727-S728. 2017
- Stereotactic Body Radiation Therapy for Colorectal Liver Metastases—Long-Term Follow-up of a Single Center's Sequential Prospective Studies. International Journal of Radiation Oncology Biology Physics. E184-E184. 2016
- Systematic Review of Patient-Reported Quality of Life Following Stereotactic Ablative Body Radiation Therapy for Primary and Metastatic Liver Cancer. International Journal of Radiation Oncology Biology Physics. E536-E537. 2016
- PHASE I STUDY OF NEO-ADJUVANT STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OPERABLE PATIENTS WITH BORDERLINE RESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA- NSCLC) (LINNEARRE I STUDY: NCT02433574). Radiotherapy and Oncology. S58-S59. 2016
- SYSTEMATIC REVIEW OF PATIENT REPORTED QUALITY OF LIFE FOLLOWING STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PRIMARY AND METASTATIC LIVER CANCER. Radiotherapy and Oncology. S62-S62. 2016
- THE MANAGEMENT OF SMALL CELL LUNG CANCER WITH RADIOTHERAPY - A PAN-CANADIAN SURVEY OF RADIATION ONCOLOGISTS. Radiotherapy and Oncology. S87-S87. 2016
- Ablative Therapy for Metastatic Breast Cancer: A Systematic Review. International Journal of Radiation Oncology Biology Physics. E15-E16. 2015
- Quantifying the Targeting Accuracy of Liver Robotic Radiosurgery. International Journal of Radiation Oncology Biology Physics. S117-S117. 2015
- Survival in Patients With Brain Metastases From Non-Small Cell Lung Cancer Treated in the Radiosurgery Era. International Journal of Radiation Oncology Biology Physics. E434-E435. 2015
- Chemoradiotherapy versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology. S286-S286. 2015
- Comparative Survival in Patients with Brain Metastases from Non-Small Cell Lung Cancer Treated before and after Implementation of Radiosurgery. Journal of Thoracic Oncology. S276-S276. 2015
- Early Results of a Quality Assurance Program in a Randomized Trial of Stereotactic Body Radiotherapy for Stage I Medically Inoperable Lung Cancer. Journal of Thoracic Oncology. S327-S327. 2015
- Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology Biology Physics. S908-S908. 2014
- Planning Target Volume Margin Suitability in Lung Stereotactic Body Radiation Therapy: A Preliminary Evaluation using Cone-beam Computed Tomography. Medical Physics. 4620-4620. 2012
- Accumulated Delivered Dose-response of Stereotactic Body Radiotherapy (SBRT) for Liver Metastases. International Journal of Radiation Oncology Biology Physics. S347-S347. 2011
- 406 INVITED Stereotactic Radiotherapy for Liver Metastases. European Journal of Cancer. S89-S89. 2011
- COST-EFFECTIVENESS ANALYSIS COMPARING CONVENTIONAL VERSUS STEREOTACTIC BODY RADIOTHERAPY FOR SURGICALLY INELIGIBLE STAGE I NON-SMALL CELL LUNG CANCER. Journal of Thoracic Oncology. S280-S281. 2011
- Changes in Liver Volume during Radiotherapy Delivered Concurrently with Sorafenib. International Journal of Radiation Oncology Biology Physics. S24-S24. 2010
- Determining Patterns of Therapy Choice in Patients Treated for Early Stage, Aggressive Histology Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics. S484-S485. 2009
- 163 OUTCOMES AND PREDICTORS OF SURVIVAL FOLLOWING CONCOMITANT AND ADJUVANT TEMOZOLOMIDE WITH RADIOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME. Radiotherapy and Oncology. S52-S52. 2009
- 17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA. Radiotherapy and Oncology. S6-S6. 2009
- Relationships between PSA bounce and definitions of biochemical failure following I-125 brachytherapy for localized, low-risk prostate cancer. Radiotherapy and Oncology. S43-S43. 2007
-
journal articles
- Stereotactic ablative radiotherapy for primary kidney cancer – An international patterns of practice survey. Clinical and Translational Radiation Oncology. 50:100891. 2025
- Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.. Radiation Oncology. 19:155. 2024
- Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.. JAMA Oncology. 10:1571-1575. 2024
- Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial.. Radiotherapy and Oncology. 202:110605. 2024
- Dosimetric Outcomes of SBRT to Ultracentral Lung Tumors: Lessons from the SUNSET Trial. International Journal of Radiation Oncology Biology Physics. 120:s106-s107. 2024
- EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.. Journal of Thoracic Oncology. 19:s566. 2024
- International Harmonization of Technical Approaches to Kidney SABR – An International Radiosurgery Consortium of the Kidney (IROCK) Contouring Project. International Journal of Radiation Oncology Biology Physics. 120:e525. 2024
- Kidney Cancer Patients' Treatment Preferences for Localized Disease. International Journal of Radiation Oncology Biology Physics. 120:e792. 2024
- Renal Function after Definitive Local Therapy for Primary Renal Cell Carcinoma: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics. 120:s73-s74. 2024
- Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase II Randomized Trial (NCT03380806). International Journal of Radiation Oncology Biology Physics. 120:s126-s127. 2024
- Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.. Cancers. 16:3334. 2024
- 163 Stereotactic Body Radiotherapy for Para-Aortic Lymph Nodes for Gynaecological Cancers. Radiotherapy and Oncology. 198:s69. 2024
- 23 Stereotactic Body Versus Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for High-Risk Prostate Cancer (HR-PC); Early Results of PBS: A Phase II Randomized Trial (NCT03380806). Radiotherapy and Oncology. 198:s13-s14. 2024
- Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.. BJU International. 2024
- Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics. 119:832-837. 2024
- Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney. European urology oncology. S2588-9311(24)00159-7. 2024
- Stereotactic Ablative Radiotherapy for Gynecological Oligometastatic and Oligoprogessive Tumors. JAMA Oncology. 10:941-941. 2024
- Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide. Practical Radiation Oncology. S1879-8500(24)00156-5. 2024
- Percées dans la prise en charge de l’hypernéphrome. CANADIAN MEDICAL ASSOCIATION JOURNAL. 196:E601-E607. 2024
- Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). International Journal of Radiation Oncology Biology Physics. 120:669-677. 2024
- Advances in the management of renal cell carcinoma. CANADIAN MEDICAL ASSOCIATION JOURNAL. 196:E235-E240. 2024
- Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.. Future Oncology. 20:2573-2588. 2024
- Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.. PLoS ONE. 19:e0314205. 2024
- Radiation recall dermatitis induced by a second course of radiation therapy in the absence of clinically significant field overlap. Oncology in Clinical Practice. 20. 2024
- Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). International Journal of Radiation Oncology Biology Physics. 118:e2-e2. 2024
- Current and Future Treatment Options in the Management of Stage III NSCLC. Journal of Thoracic Oncology. 18:1478-1491. 2023
- 5-Year Renal Function Outcomes after SABR for Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium of the Kidney (IROCK). International Journal of Radiation Oncology Biology Physics. 117:S84-S84. 2023
- 976P Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone. Annals of Oncology. 34:S605-S605. 2023
- Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). International Journal of Radiation Oncology Biology Physics. 117:e434-e434. 2023
- Final Results from a Prospective Randomized Pilot Trial of Stereotactic Body Radiation Therapy vs. Radiofrequency Ablation for the Management of Small Renal Masses (RADSTER). International Journal of Radiation Oncology Biology Physics. 117:S82-S82. 2023
- Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer – A Secondary Analysis of the LUSTRE Randomized Trial. International Journal of Radiation Oncology Biology Physics. 117:S171-S171. 2023
- Radiotherapy for Liver Cancer: An International Multi-Centre Pooled Analysis of 925 Cases. International Journal of Radiation Oncology Biology Physics. 117:e319-e320. 2023
- 113 Final Results from a Prospective Randomized Pilot Trial of Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses (RADSTER). Radiotherapy and Oncology. 186:S52-S52. 2023
- 128 Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer - A Secondary Analysis of the Lustre Randomized Trial. Radiotherapy and Oncology. 186:S59-S59. 2023
- 146 Five-Year Renal Function Outcomes After Sabr for Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium of the Kidney (IROCK). Radiotherapy and Oncology. 186:S66-S67. 2023
- 147 Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). Radiotherapy and Oncology. 186:S67-S67. 2023
- 300 Stereotactic Radiotherapy for the Re-Treatment of Pelvic and Para-Aortic Disease in Gynecologic Cancers. Radiotherapy and Oncology. 186:S127-S128. 2023
- Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis. Advances in Radiation Oncology. 8:101238-101238. 2023
- The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma. Cancers. 15:3672-3672. 2023
- BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics. 116:601-610. 2023
- Adjuvant therapy for renal cell carcinoma. Journal of the Canadian Urological Association. 17:E154-63. 2023
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. 41:TPS750-TPS750. 2023
- Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study. Clinical Oncology. 35:e182-e188. 2023
- Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer. Journal of Thoracic Disease. 15:423-433. 2023
- Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history. PLoS ONE. 18:e0294154-e0294154. 2023
- Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone. Frontiers in Oncology. 13:1290691. 2023
- The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada. Frontiers in Oncology. 13:1210945. 2023
- 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). The Lancet Oncology. 23:1508-1516. 2022
- LUSTRE: A Phase III Randomized Trial of Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Hypofractionated Radiotherapy (CRT) for Medically Inoperable Stage I Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. 114:1061-1062. 2022
- Development of a Support Vector Machine-Based Tool for Survival Prediction after Stereotactic Body Radiotherapy for Liver Metastases Using Multi-Institutional Data. International Journal of Radiation Oncology Biology Physics. 114:e122-e122. 2022
- Long-Term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multicenter Analysis from IROCK (International Radiosurgery Oncology Consortium for Kidney). International Journal of Radiation Oncology Biology Physics. 114:S77-S77. 2022
- Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial. Clinical and Translational Radiation Oncology. 37:145-152. 2022
- Radiation Dose, Technique and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. 114:e411-e411. 2022
- Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). Clinical Genitourinary Cancer. 20:e353-e361. 2022
- 139: Radiotherapy Dose, FDG-PET Utilization and Survival Outcomes of Unresected Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Ontario Population Outcomes of Contemporary Radiotherapy Alone and Standard of Care Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S59-S60. 2022
- 33: A Prospective Randomized Parallel-Controlled Pilot Trial of Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses - Initial Results. Radiotherapy and Oncology. 174:S17-S17. 2022
- 44: Long-Term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multi-Centre Analysis from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Radiotherapy and Oncology. 174:S21-S22. 2022
- 68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. Radiotherapy and Oncology. 174:S31-S31. 2022
- 75: Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncologic and Renal Function Outcomes. Radiotherapy and Oncology. 174:S34-S34. 2022
- 88: Outcomes of Radiotherapy Alone for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in Patients Unfit for Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S39-S39. 2022
- EP04.02-002 International Consensus on Actions to Improve Lung Cancer Survival: Delphi Method in the International Cancer Benchmarking Partnership. Journal of Thoracic Oncology. 17:S260-S261. 2022
- Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology. 7:100899-100899. 2022
- Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. Acta Oncologica. 61:705-713. 2022
- Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.. Acta Oncologica. 61:705-713. 2022
- OC-0104 Stereotactic radiation for treatment of oligometastases (SABR-COMET) – Extended long-term outcomes. Radiotherapy and Oncology. 170:S88-S88. 2022
- Comparing treatment modalities for hepatocellular carcinoma: the value of network meta-analyses. Acta Oncologica. 61:495-495. 2022
- Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer – a systematic review and network meta-analysis of survival data. Acta Oncologica. 61:484-494. 2022
- The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy—rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial. Translational Cancer Research. 11:918-927. 2022
- A four port circularly polarized printed multiple‐input multiple‐output antenna with enhanced isolation. International Journal of Communication Systems. 35. 2022
- Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus?. International Journal of Radiation Oncology Biology Physics. 112:586-589. 2022
- The role of stereotactic body radiation therapy in the management of pulmonary metastases: a systematic review. Precision Radiation Oncology. 6:85-95. 2022
- An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership. Cancer Control. 29:107327482211193-107327482211193. 2022
- Stereotactic body radiotherapy for osseous low alpha–beta resistant metastases for pain relief—SOLAR-P. Radiation Oncology. 16:170. 2021
- 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017. Radiotherapy and Oncology. 163:S44-S44. 2021
- 170: Real-World Outcomes of Chemoradiation and Consolidative Durvalumab in Unresectable Stage III Non-Small-Cell Lung Cancer – A Systematic Review. Radiotherapy and Oncology. 163:S72-S72. 2021
- 23: Cost-Effectiveness of Sabr in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-Comet Randomized Trial. Radiotherapy and Oncology. 163:S13-S13. 2021
- Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?. Journal of Thoracic Oncology. 16:1607-1609. 2021
- Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 7:1333-1333. 2021
- Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 15:281-286. 2021
- Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse. Current Oncology. 28:2778-2788. 2021
- Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer – Results from a Prospective Cohort Study. Clinical Oncology. 33:468-475. 2021
- Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio’s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]. European Urology Focus. 7:404-405. 2021
- Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report. Current Oncology. 28:390-395. 2021
- Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma. Frontiers in Oncology. 11:634830. 2021
- A pilot study of stereotactic boost for malignant epidural spinal cord compression: clinical significance and initial dosimetric evaluation. Radiation Oncology. 15:267. 2020
- Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer. 20:380. 2020
- Stereotactic Radiotherapy for Oligoprogression in Metastatic Kidney Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Prospective Phase II Multi-Centre Study. International Journal of Radiation Oncology Biology Physics. 108:S27-S28. 2020
- Development of Best Practices of Peer Review for Lung Radiation Therapy. JCO Oncology Practice. 16:e1181-e1191. 2020
- 194: Cardiac Toxicity in Central Non-Small Cell Lung Tumours Treated with Stereotactic Body Radation Therapy (SBRT) - Is There A “No-Flutter Zone”?. Radiotherapy and Oncology. 150:S83-S83. 2020
- 202: Cost-Effectiveness of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) in the Treatment of Localized Renal Cell Carcinoma. Radiotherapy and Oncology. 150:S86-S86. 2020
- 212: Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study. Radiotherapy and Oncology. 150:S90-S90. 2020
- 36: Surgery Versus SBRT for Early-Stage Nsclc in Octogenarians and Nonagenarians: An Overall Survival Difference?. Radiotherapy and Oncology. 150:S19-S19. 2020
- 8: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-Comet Randomized Trial. Radiotherapy and Oncology. 150:S7-S7. 2020
- 9: A Phase Ii Multicentre Trial of Stereotactic Radiotherapy for Oligoprogression in Metastatic Kidney Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy. Radiotherapy and Oncology. 150:S7-S8. 2020
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology. 38:2830-2838. 2020
- A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Clinical Genitourinary Cancer. 18:e410-e415. 2020
- Chest Wall Toxicity after Stereotactic Radiation in Early Lung Cancer: A Systematic Review. Current Oncology. 27:179-189. 2020
- Chest Wall Toxicity after Stereotactic Radiation in Early Lung Cancer: A Systematic Review.. Current Oncology. 27:179-189. 2020
- Overall and chemotherapy‐free survival following stereotactic body radiation therapy for abdominopelvic oligometastases. Journal of Medical Imaging and Radiation Oncology. 64:563-569. 2020
- A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology. 38:5065-5065. 2020
- Assessing the Variability and Quality of Lung Stereotactic Radiation Therapy Treatment Plans Using a Web-Based Crowdsourcing Platform. Practical Radiation Oncology. 10:e118-e127. 2020
- Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.. Cancer Treatment and Research Communications. 25:100265-100265. 2020
- The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer. Cancer Treatment and Research Communications. 25:100246-100246. 2020
- Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics. 105:943-947. 2019
- Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 19:816. 2019
- Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists. Breast Journal. 25:1222-1224. 2019
- The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus. 5:958-969. 2019
- 122 A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. Radiotherapy and Oncology. 139:S53-S53. 2019
- 126 Engaging Inter-Professional Collaboration to Improve Resident Treatment Planning Knowledge and Skills. Radiotherapy and Oncology. 139:S55-S55. 2019
- 146 A Comparison of Stereotactic Body Radiotherapy Modalities: Volumetric Modulated Arc Therapy Versus Intensity Modulated Radiation Therapy in Treatment of Kidney Cancer. Radiotherapy and Oncology. 139:S63-S63. 2019
- 19 Stereotactic Body Radiotherapy for Large Primary Large Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Radiotherapy and Oncology. 139:S11-S11. 2019
- 91 Quality of Life Outcomes After Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial. Radiotherapy and Oncology. 139:S41-S41. 2019
- 92 Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET. Radiotherapy and Oncology. 139:S41-S42. 2019
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta. 495:355-357. 2019
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. Clinical Oncology. 31:479-485. 2019
- Surgery after Chemoradiotherapy in Patients with Stage III (n2 or N3, Excluding T4) Non-Small-Cell Lung Cancer: A Systematic Review. Current Oncology. 26:398-404. 2019
- Single versus multifraction radiotherapy for spinal cord compression: A systematic review and meta-analysis. Radiotherapy and Oncology. 134:55-66. 2019
- Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review. Journal of Radiation Oncology. 8:13-21. 2019
- A method for optimizing planning target volume margins for patients receiving lung stereotactic body radiotherapy. Physics in Medicine and Biology. 63:195015-195015. 2018
- SUNSET: Stereotactic Radiation for Ultracentral Non–Small-Cell Lung Cancer—A Safety and Efficacy Trial. Clinical Lung Cancer. 19:e529-e532. 2018
- Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 124:934-942. 2018
- Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives. Breast Cancer: Targets and Therapy. Volume 9:13-23. 2018
- Identifying Barriers to Accrual in Radiation Oncology Randomized Trials. Current Oncology. 24:524-530. 2017
- Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiation Oncology. 12:110. 2017
- Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. International Journal of Radiation Oncology Biology Physics. 99:388-395. 2017
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. 18:436-440.e1. 2017
- Ablative Therapies in Metastatic Breast Cancer: A Systematic Review. Breast Cancer Research and Treatment. 164:13-25. 2017
- Comparative Survival in Patients with Brain Metastases from Non-small-Cell Lung Cancer Treated before and after Implementation of Radiosurgery. Current Oncology. 24:146-151. 2017
- Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer. 18:250-254. 2017
- Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey. Clinical Oncology. 28:667-667. 2016
- 159: Phase I Study of NEO-Adjuvant Stereotactic Body Radiotherapy (SBRT) in Operable Patients with Borderline Resectable Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (Linnearre I Study: NCT02433574). Radiotherapy and Oncology. 120:S58-S59. 2016
- 169: Systematic Review of Patient Reported Quality of Life Following Stereotactic Ablative Body Radiotherapy for Primary and Metastatic Liver Cancer. Radiotherapy and Oncology. 120:S62-S62. 2016
- 240: The Management of Small Cell Lung Cancer with Radiotherapy - A Pan-Canadian Survey of Radiation Oncologists. Radiotherapy and Oncology. 120:S87-S87. 2016
- Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 99:180-185. 2016
- Metformin for chemo-radio-sensitization of NSCLC. Radiotherapy and Oncology. 120:363-364. 2016
- Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists. Current Oncology. 23:184-195. 2016
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 17:142-149. 2016
- Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy. International Journal of Radiation Oncology Biology Physics. 94:729-737. 2016
- Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases. International Journal of Radiation Oncology Biology Physics. 93:639-648. 2015
- Accuracy of Robotic Radiosurgical Liver Treatment Throughout the Respiratory Cycle. International Journal of Radiation Oncology Biology Physics. 93:916-924. 2015
- Innovation: Development of a Virtual Radiation Oncologist Consultation Service. Journal of Medical Imaging and Radiation Sciences. 46:S5-S5. 2015
- Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions. Journal of the Canadian Urological Association. 9:275-275. 2015
- Utilization of Stereotactic Ablative Radiotherapy in the Management of Oligometastatic Disease. Current Oncology. 21:115-117. 2014
- Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non–Small-Cell Lung Cancer. JCO Oncology Practice. 10:e130-e136. 2014
- The Canadian Association of Radiation Oncology Scope of Practice Guidelines for Lung, Liver and Spine Stereotactic Body Radiotherapy. Clinical Oncology. 24:629-639. 2012
- Sci-Thur AM: Planning - 06: Planning target volume margin suitability in lung stereotactic body radiation therapy: A preliminary evaluation using cone-beam computed tomography. Medical Physics. 39:4620-4620. 2012
- Sorafenib and Radiation Therapy for the Treatment of Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer. 43:344-348. 2012
- Erratum: Stereotactic body radiotherapy for colorectal liver metastases. Cancer. 118:2776-2776. 2012
- Radiotherapy for Liver Metastases: A Review of Evidence. International Journal of Radiation Oncology Biology Physics. 82:1047-1057. 2012
- Impact of Tumor Size and Volume on Outcomes following Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. 81:S585-S585. 2011
- Stereotactic body radiotherapy for colorectal liver metastases. Cancer. 117:4060-4069. 2011
- Image-Guided Radiotherapy Strategies in Upper Gastrointestinal Malignancies. Frontiers of Radiation Therapy and Oncology. 43:315-330. 2011
- Stereotactic Body Radiotherapy for Colorectal Liver Metastases: A Pooled Analysis. International Journal of Radiation Oncology Biology Physics. 78:S56-S57. 2010
- Emerging Role of Radiotherapy in the Management of Liver Metastases. Cancer Journal. 16:150-155. 2010
- Radiotherapy for Oncologic Emergencies on Weekends: Examining Reasons for Treatment and Patterns of Practice at a Canadian Cancer Centre. Current Oncology. 16:55-60. 2009
-
preprints
- Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected Locally Advanced Non-Small Cell Lung Cancer treated with chemo- radiotherapy. 2024
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial 2020